<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490256</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00002654</org_study_id>
    <nct_id>NCT00490256</nct_id>
  </id_info>
  <brief_title>Modified Perfusion for Neonatal Aortic Arch Reconstruction</brief_title>
  <official_title>Evaluation of a Modified Perfusion Strategy for Neonatal Aortic Arch Reconstruction: Does Perfusing the Lower Body During Arch Repair Help?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Healthcare of Atlanta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Even though the lower part of the body does receive some blood supply during Cardiopulmonary
      Bypass(CPB) surgery, it may not be enough. As a result of this lowered blood supply, there
      are complications associated with CPB and clamping of the aorta. These include complications
      with the stomach, intestines and kidneys.

      The hypotheses of this study are that increased lower body perfusion during aortic arch
      reconstruction will decrease intestinal ischemia and the incidence of necrotizing
      enterocolitis, improve renal function in the postoperative period, and shorten both intensive
      care unit and hospital length of stay.

      The purpose of this research study is to provide the lower part of the body and its organs
      with possibly more blood supply with a modified form of cardiopulmonary bypass and see if
      this additional blood supply helps to decrease complications of the kidney, stomach and
      intestines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As the aorta is repaired, the child has no circulation to the body or brain. While short
      periods of circulatory arrest were well tolerated, a modified technique called selective
      cerebral perfusion was developed to maintain blood flow to the brain during aortic repairs so
      as to allow for less hurried repairs with less concern over brain ischemia and injury.

      Selective cerebral perfusion is designed to provide flow to the brain via the right carotid
      artery and collateral intracranial vessels while the aortic arch is isolated for repair. It
      is felt that collateral vessels also allow some perfusion of the lower body, but the adequacy
      of lower body perfusion during selective cerebral perfusion has not been well documented.
      While it is clear that some blood reaches the lower body, the incidence of renal and
      gastrointestinal complications following cardiac repairs involving aortic arch
      reconstructions remains significant.

      The goal of this proposal is to evaluate a simple modification of the standard selective
      cerebral perfusion protocol designed to increase perfusion to the lower body during aortic
      arch reconstructions. Essentially all children who undergo aortic arch reconstruction at
      Egleston hospital have either a femoral or umbilical artery catheter in place for routine
      monitoring. During selective cerebral perfusion, the descending thoracic aorta is clamped, so
      the lower body arterial line is not a useful monitor at that point. We propose to connect a
      pressure line from the cardiopulmonary bypass circuit to the lower body arterial catheter,
      allowing for increased perfusion of the lower body through the femoral/umbilical arterial
      catheter during selective cerebral perfusion We will monitor simultaneous near infra-red
      spectroscopy of the brain, flank, and thigh to determine the adequacy of oxygen delivery to
      the brain, kidney, and lower body musculature during the procedure. Near infra-red
      spectroscopy provides a measure of the oxygenation of hemoglobin in arterial, capillary, and
      venous blood within the path of an infra-red sensor. Blood samples will be collected before
      skin incision, at the end of the procedure, and at 3, 12, and 24 hours after arrival to the
      intensive care unit. Intestinal fatty acid binding protein (i-FABP) and c-reactive protein
      (CRP) serum levels will be measured at each timepoint as markers of intestinal ischemia and
      generalized inflammation respectively. The incidence of documented or suspected necrotizing
      enterocolitis prior to hospital discharge and the time required to achieve full enteral feeds
      will be recorded. Renal function will be assayed by the maximal change from preoperative to
      postoperative serum creatinine, normalized urine output per 12 hour period following surgery,
      total diuretic dose per day, and daily creatinine clearance for the first 3 days after
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intestinal Fatty Acid Binding Protein and C-reactive Protein</measure>
    <time_frame>Baseline and 0, 3, 12, and 24 hours after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>iFAB Post-op</measure>
    <time_frame>Immediate postop</time_frame>
    <description>intestinal fatty acid binding protein level immediately postop</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral and Lower Body Near Infra-red Spectroscopy Measures</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Aortic Arch Hypoplasia or Atresia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Arm 1 is the control arm. This arm will receive the standard cardiopulmonary bypass circuit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm is the modified selective perfusion arm. This arm will receive the modified cardiopulmonary circuit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Modified Selective Cerebral Perfusion</intervention_name>
    <description>Modified Selective perfusion is a cardiopulmonary bypass circuit that has been modified to allow blood flow to the lower body as well as the upper body while the surgery is being performed.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis including aortic coarctation, arch hypoplasia, or interrupted aortic arch
             which requires cardiopulmonary bypass for repair

          -  age less than 1 year

          -  parental consent for participation

        Exclusion Criteria:

          -  prior aortic arch operations

          -  emergency operation

          -  operating surgeon decides that selective cerebral perfusion is not indicated

          -  Documented renal insufficiency (creatinine &gt; 2.0) or evidence of bowel ischemia prior
             to surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Kirshbom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jeffries HE, Wells WJ, Starnes VA, Wetzel RC, Moromisato DY. Gastrointestinal morbidity after Norwood palliation for hypoplastic left heart syndrome. Ann Thorac Surg. 2006 Mar;81(3):982-7.</citation>
    <PMID>16488706</PMID>
  </reference>
  <reference>
    <citation>Asou T, Kado H, Imoto Y, Shiokawa Y, Tominaga R, Kawachi Y, Yasui H. Selective cerebral perfusion technique during aortic arch repair in neonates. Ann Thorac Surg. 1996 May;61(5):1546-8.</citation>
    <PMID>8633985</PMID>
  </reference>
  <reference>
    <citation>Pigula FA, Siewers RD, Nemoto EM. Regional perfusion of the brain during neonatal aortic arch reconstruction. J Thorac Cardiovasc Surg. 1999 May;117(5):1023-4.</citation>
    <PMID>10220701</PMID>
  </reference>
  <reference>
    <citation>Pigula FA, Gandhi SK, Siewers RD, Davis PJ, Webber SA, Nemoto EM. Regional low-flow perfusion provides somatic circulatory support during neonatal aortic arch surgery. Ann Thorac Surg. 2001 Aug;72(2):401-6; discussion 406-7.</citation>
    <PMID>11515874</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2007</study_first_posted>
  <results_first_submitted>July 8, 2011</results_first_submitted>
  <results_first_submitted_qc>July 8, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2011</results_first_posted>
  <last_update_submitted>May 21, 2014</last_update_submitted>
  <last_update_submitted_qc>May 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Brian Kogon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Selective Cerebral Perfusion</keyword>
  <keyword>Renal Complications</keyword>
  <keyword>Gastrointestinal Complications</keyword>
  <keyword>Aortic Arch Reconstruction</keyword>
  <keyword>Modified Perfusion</keyword>
  <keyword>Cardiopulmonary Bypass</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Cardiac Defects</keyword>
  <keyword>intestinal ischemia</keyword>
  <keyword>necrotizing entercolitis</keyword>
  <keyword>Near Infra-red spectroscopy</keyword>
  <keyword>Creatinine</keyword>
  <keyword>C-reactive protein levels</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Arm 1 is the control arm. This arm will receive the standard cardiopulmonary bypass circuit.</description>
        </group>
        <group group_id="P2">
          <title>Experimental</title>
          <description>This arm is the modified selective perfusion arm. This arm will receive the modified cardiopulmonary circuit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intraoperative Portion of the Study</title>
              <participants_list>
                <participants group_id="P1" count="7">Intraoperative management</participants>
                <participants group_id="P2" count="7">Intraoperative management</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Arm 1 is the control arm. This arm will receive the standard cardiopulmonary bypass circuit.</description>
        </group>
        <group group_id="B2">
          <title>Experimental</title>
          <description>This arm is the modified selective perfusion arm. This arm will receive the modified cardiopulmonary circuit.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.9" spread="8.5"/>
                    <measurement group_id="B2" value="4.7" spread="2.9"/>
                    <measurement group_id="B3" value="7.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intestinal Fatty Acid Binding Protein and C-reactive Protein</title>
        <time_frame>Baseline and 0, 3, 12, and 24 hours after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral and Lower Body Near Infra-red Spectroscopy Measures</title>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>iFAB Post-op</title>
        <description>intestinal fatty acid binding protein level immediately postop</description>
        <time_frame>Immediate postop</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Arm 1 is the control arm. This arm will receive the standard cardiopulmonary bypass circuit.</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>This arm is the modified selective perfusion arm. This arm will receive the modified cardiopulmonary circuit.</description>
          </group>
        </group_list>
        <measure>
          <title>iFAB Post-op</title>
          <description>intestinal fatty acid binding protein level immediately postop</description>
          <units>mcg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1590" spread="1188"/>
                    <measurement group_id="O2" value="564" spread="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Arm 1 is the control arm. This arm will receive the standard cardiopulmonary bypass circuit.</description>
        </group>
        <group group_id="E2">
          <title>Experimental</title>
          <description>This arm is the modified selective perfusion arm. This arm will receive the modified cardiopulmonary circuit.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers for analysis</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul Kirshbom, MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-785-6330</phone>
      <email>pkirshb@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

